FDA Alert
FDA Alert
03/21/2024

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approved resmetirom for the treatment of adults with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis.
03/21/2024
FDA Alert
FDA Alert
03/04/2024

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin as a first-line regimen for the management of patients with metastatic pancreatic adenocarcinoma.
03/04/2024
FDA Alert
FDA Alert
06/15/2023

Jessica Ganga

Jessica Ganga
The FDA approved the first treatment for pediatric patients who experience functional constipation
06/15/2023
FDA Alert
FDA Alert
06/01/2023

Jessica Ganga

Jessica Ganga
The FDA has approved the first orally administered treatment for the gut infection—clostridioides difficile.
06/01/2023
FDA alert
FDA alert
05/25/2023

Jessica Ganga

Jessica Ganga
After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.
05/25/2023
c difficile
c difficile
01/24/2020
The FDA has expanded the approval of a drug used for the treatment of C. difficile infection to include pediatric patients aged 6 months and older.
01/24/2020
Hepatitis C
Hepatitis C
09/26/2019
The FDA has expanded the approval of a new option for the treatment of adults and children aged 12 years or older or weighing at least 99 pounds with chronic hepatitis C virus genotypes 1, 2, 3, 4, 5, or 6...
09/26/2019
FDA
FDA
09/13/2019
The NHE3 sodium transport inhibitor was approved for use after results from 2 clinical trials showed increased bowel movements and decreased abdominal pain among individuals with IBS-C.
09/13/2019
Hepatitis C
Hepatitis C
08/29/2019
The FDA issued a drug safety warning after more than 60 individuals experienced liver injury after they received treatment with 1 of 3 medications for hepatitis C virus.
08/29/2019
Ulcerative Colitis
Ulcerative Colitis
07/26/2019
The FDA issued a safety alert after results of a safety clinical trial showed increased risk of blood clots and death with higher dosages of the janus kinase inhibitor.
07/26/2019